US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.17

+1.754.33%

Post-market: 42.170.00000.00%19:30 EDT

Volume:151.58K

Turnover:6.33M

Market Cap:314.17M

PE:- -

High:42.27

Open:40.52

Low:40.52

Close:40.42

52wk High:43.44

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.88

T/O Rate:2.03%

Dividend:0.28

Dividend Rate:0.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule

Jefferies Initiates Twist Bioscience at Hold With $150 Price Target

MT Newswires Live

Editas Medicine receives approval to initiate clinical trial of EDIT-401

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative

Simply Wall St.

HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment

MT Newswires Live

Twist Bioscience Corporation : Jefferies Initiates Coverage with Hold Rating; Target Price $150

THOMSON REUTERS

Trading DAY-Stocks, Bonds in Delicate Dance

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Twist Bioscience CEO Emily M. Leproust Disposes of USD 910,033 in Common Shares

Vertex to Report Q3 2026 Financial Results, Host Conference Call and Webcast

Moderna, Merck Climb on Collaboration with Tempus

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Twist Bioscience Price Target Raised to $215.00/Share from $112.00 by Barclays

Moderna Price Target Raised to $95.00/Share from $89.00 by Morgan Stanley

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IDNA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":42.17,"timestamp":1791576000000,"preClose":40.42,"halted":0,"volume":151584,"hourTrading":{"tag":"盘后","latestPrice":42.17,"preClose":42.17,"latestTime":"19:30 EDT","volume":18756,"amount":791067.45,"timestamp":1791588605724,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04329539831766452,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Market Closed","change":1.75,"latestTime":"10-09 16:00:00 EDT","open":40.52,"high":42.27,"low":40.52,"amount":6330134.197439999,"amplitude":0.043295,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":40.42,"sharesOutstanding":5100000,"nav":40.333384,"aum":306533718.4,"dividendRate":0.006687,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.42,"preClose":40.42,"latestTime":"07:38 EDT","volume":3,"amount":121.22320199999999,"timestamp":1791545933537,"change":0,"changeRate":0,"amplitude":0.000495},"postHourTrading":{"tag":"盘后","latestPrice":42.17,"preClose":42.17,"latestTime":"19:30 EDT","volume":18756,"amount":791067.45,"timestamp":1791588605724,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8829635299324997,"impliedVol":0.1291,"impliedVolPercentile":0.2271},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8829635299324997,"shares":7450000,"dividePrice":0.282,"high":42.27,"amplitude":0.043295,"preClose":40.42,"low":40.52,"week52Low":23.9,"pbRate":"--","week52High":43.44,"institutionHeld":0,"latestPrice":42.17,"eps":0,"divideRate":0.006687,"volume":151584,"delay":0,"ttmEps":0,"open":40.52,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.65,"twentyDayClose":38.06,"sixtyDayClose":32.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673077189","title":"CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673077189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673077189?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:30","pubTimestamp":1791462600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310, its investigational CRISPR/Cas9","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377269/0/en/crispr-therapeutics-to-present-late-breaking-data-at-the-american-heart-association-aha-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","CRSP","BK4556","LU1861559042.SGD","SYNB","BK4107","BK4588","LU1861558580.USD","AGT","BK4139","BK4585","ARKG","AFG","IDNA","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074298","title":"Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074298","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074298?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:01","pubTimestamp":1791460900,"startTime":"0","endTime":"0","summary":"Incyte updates financial calendar with third-quarter results conference call and webcast scheduleIncyte scheduled its Q3 2026 results release for Oct. 29, 2026, at 7:00 a.m. ET.Management will host th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLbL9kYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDNA","BK4532","INCY","BK4585","BK4588","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507199","title":"Jefferies Initiates Twist Bioscience at Hold With $150 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673507199?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458909,"startTime":"0","endTime":"0","summary":"Twist Bioscience (TWST) has an average rating of overweight and mean price target of $150.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","IDNA","GNOM","TWST","BK4585","WDNA","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071338","title":"Editas Medicine receives approval to initiate clinical trial of EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071338?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457602,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IDNA","BK4556","GDOC","HYLG","NVIB","MEDX","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673714960","title":"Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673714960","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673714960?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457200,"startTime":"0","endTime":"0","summary":"Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377124/0/en/editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-edit-401-in-patients-with-hyperlipidemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","HYLG","SYNB","GDOC","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017021","title":"Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:26","pubTimestamp":1791444398,"startTime":"0","endTime":"0","summary":"Revolution Medicines has already started treating patients in RASolute 309, a global Phase 3 trial testing RASONQUE plus zoldonrasib as first line therapy against standard gemcitabine and nab paclitaxel in metastatic RAS G12D pancreatic cancer, with progression free and overall survival as dual primary endpoints.\nThe study targets RAS G12D, the most prevalent RAS mutation across cancers, where roughly 61,000 new U.S. patients each year currently have no approved targeted therapy. This puts...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","BK4139","LU2298322129.HKD","BK4512","LU1861219969.SGD","BK4141","IE0002141913.USD","LU1548497426.USD","ONG","IE00BFTCPJ56.SGD","CANC","LU1861215975.USD","ON","LU1720051017.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2357305700.SGD","LU1720051108.HKD","LU1854103824.USD","LU0124384867.USD","BK4588","IE0009355771.USD","IE00BZ199S13.USD","LU0348723411.USD","LU0724618433.USD","IDNA","PTH","LU2360107325.USD","LU1861214812.USD","LU0320765992.SGD","IE0009354923.USD","ONX","LU1854104046.USD","RVMD","BK4605","LU1983260115.SGD","BBH","LU1861220033.SGD","IE00BFMHRM44.USD","LU0109394709.USD","IE00BD6J9T35.USD","LU1978683503.SGD","BK4585","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673040775","title":"HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673040775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673040775?lang=en_us&edition=fundamental","pubTime":"2026-10-08 12:43","pubTimestamp":1791434637,"startTime":"0","endTime":"0","summary":"HanchorBio's  subsidiary, FBD Biologics, has submitted an Investigational New Drug application to the Taiwan Food and Drug Administration  for clinical trial review of HCB303, a trispecific fusion protein being developed for the potential treatment of solid tumors.The application follows the recent receipt of approval from the U.S. Food and Drug Administration for HCB303, according to a Wednesday filing to the Taiwan Stock Exchange.TFDA approval and applicable institutional ethics approval will pave the way for patient enrollment for the trial in Taiwan.Following receipt of the required regulatory and institutional ethics approvals, the company plans to conduct Phase I, Phase II, and Phase III clinical trials sequentially.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDNA","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673047449","title":"Twist Bioscience Corporation : Jefferies Initiates Coverage with Hold Rating; Target Price $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2673047449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673047449?lang=en_us&edition=fundamental","pubTime":"2026-10-08 11:44","pubTimestamp":1791431098,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","WDNA","ARKG","TWST","BK4585","GNOM","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048285","title":"Trading DAY-Stocks, Bonds in Delicate Dance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048285","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048285?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:00","pubTimestamp":1791406800,"startTime":"0","endTime":"0","summary":"TRADING DAY-Stocks, bonds in delicate danceORLANDO, Florida, Oct 7 (Reuters)-A sea of red swept across globalstockson Wednesday as the bond market selloff picked up again and lifted long-dated US yiel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","IE00B3S45H60.SGD","LU0234570918.USD","LU1979441026.SGD","LU2125154935.USD","LU2168564065.EUR","LU1791710400.SGD","SGXZ80539844.SGD","NVD2.UK","BK4568","LU0211327993.USD","BK4548","LU0823421416.USD","LU0787776722.HKD","LU2125909759.SGD","LU1429558221.USD","GASZ","LU0154236417.USD","LU0266013472.USD","GB00BDT5M118.USD","LU1145028129.USD","NULC","LU1280957306.USD","LU2237443978.SGD","LU0689626769.HKD","LU1720051017.SGD","LU2063271972.USD","LU2896262040.SGD","LU2491050154.USD","LU0316494557.USD","BK4566","LU0061474960.USD","NVDY","USXF","LU0274383776.USD","LU2326559502.SGD","09788","LU2602419157.SGD","BK4605","MARS","LU2430703178.SGD","CNEQ","LU0251142724.SGD","ELOL","LU0289960550.SGD","LU2462591350.SGD","IE00BDRTCR15.USD","LU2471134952.CNY","LU0345770993.USD","LU0724617625.USD","LU2083900584.USD","IE00BWXC8680.SGD","MULL","LU2244417387.USD","LU2357627491.SGD","LU2092627202.USD","HK0000914660.USD","LU2237443622.USD","LU2087625088.SGD","LU2463028550.USD","LU1267930813.SGD","LU2543165471.USD","MRNX","SMHX","LU0215105999.USD","NVII","LU1116320901.HKD","LU2077746001.SGD","EFIV","MUU","LU1778281490.HKD","LU0310800379.SGD","LU2125154778.USD","MRNA","LU1718418525.SGD","LU2133065610.SGD","LU2125909247.SGD","LU2357125470.USD","IE0009356076.USD","IE0034235303.USD","FDTX","IE00B3M56506.USD","LU0345770308.USD","2NVD.UK","LU0210536198.USD","LU0882574139.USD","LU1815333072.USD","SPCH","LU0265550359.USD","HK0000304805.HKD","BK4139","LU0061475181.USD","ANV","IE00BQXX3C00.GBP","BK4585","IE00BZ1G4Q59.USD","IE00BKPKM429.USD","MADE","LU0289961442.SGD","LU0308772762.SGD","FXL","LU0979878070.USD","LU1127390331.HKD","WSPC","HK0000304797.USD","LU0079474960.USD","07788","ARTY","LU2637965513.SGD","IE0009G5SDU7.USD","LU1400636491.USD","NVDG","SG9999002224.SGD","LU2491050071.SGD","IE00BYXW3230.USD","LU1261432733.SGD","LGHT","LU0143551892.USD","SG9999000418.SGD","XNTK","IE00B7KXQ091.USD","LU2417539215.USD","LU0742534661.SGD","IETC","IE00BFSS7M15.SGD","LU1861558580.USD","LU0965509010.AUD","09388","AGOX","3NVD.UK","LU0823414478.USD","FAI","LU0127658192.USD","LU1861127337.USD","LU0786609619.USD","LU2065171402.SGD","LU2505996681.GBP","LU2552382132.HKD","LU2487616109.SGD","LU1935043452.HKD","LU0861579265.USD","LU1551013425.SGD","SG9999015945.SGD","IE00B3SWFQ91.USD","LU0251131958.USD","LU1861215975.USD","HK0000532082.HKD","LU2746668974.SGD","LU2750360997.AUD","LU0347712357.USD","DIPS","LU1691799644.USD","LU0211328371.USD","LU1037948897.HKD","LU2430703095.HKD","BK4527","LU0069063385.USD","SG9999014575.USD","LU2506951792.HKD","LU0642271901.SGD","LU0109392836.USD","LU0198837287.USD","LU0323240290.USD","LU2087621335.USD","SPCG","SPCX","LU1989764664.SGD","LU1623119135.USD","LU1366333091.USD","LU2552382215.SGD","LU1923623000.USD","LU2360107168.USD","LU1674673691.USD","LU2048586759.USD","LU0080751232.USD","LU0203347892.USD","LU0106261372.USD","LU2413666426.HKD","LU2272731865.HKD","IE00B19Z8W00.USD","LU0823434740.USD","BK4532","LU1496350502.SGD","CAT","LU2242649171.HKD","IE00B7SZLL34.SGD","LU2860962120.EUR","LU1974910355.USD","LU1064131342.USD","NVD3.UK","LU0823421333.USD","LU0965508806.USD","IE00B4JS1V06.HKD","LU1935042215.USD","LU1316542783.SGD","LU2265009873.SGD","LU1720051108.HKD","LU0225283273.USD","BK4554","LU0124676726.USD","IE0004091025.USD","SG9999014914.USD","SG9999014880.SGD","LU2047632596.USD","YSPC","BOBP","SPAL","SGXZ31699556.SGD","FTXL","NVDW","LU0170899867.USD","07388","LU0795875086.SGD","LU1035773651.USD","LU0708994859.HKD","LU1242518857.USD","LU0889566641.SGD","SG9999017495.SGD","IE0004445239.USD","LU2360032135.SGD","LU1935043023.USD","LU1934455194.USD","LU2106854487.HKD","LU2100268510.USD","WARP","ORBX","BK4612","BK4512","LU0081259029.USD","LU0107464264.USD","LU1003077747.HKD","LU2092937148.SGD","LU0868494617.USD","LU2264538146.SGD","SNPE","NVDS","IE000ITXATA3.USD","WDNA","LU2433249047.HKD","IE000KEQY171.SGD","LU2461242641.AUD","MUG","LU0011850046.USD","NVDQ","FTEC","LU1989772923.USD","NVIW.SI","LU0077335932.USD","LU2505996509.AUD","LU2954938101.SGD","IE000M9KFDE8.USD","LU2347655073.USD","LU2213496289.HKD","SPTE","IE00BJJMRY28.SGD","MUD","XLK","CHPX","SGXZ51526630.SGD","EXI","LU1670756490.USD","AIPI","BK4551","BK4550","LU2168564222.USD","IE00B4YYXB79.USD","USD","IE00BMPRXN33.USD","CATG","LU1868837300.USD","LU0545039389.USD","BK4501","LU0256863902.USD","GAMR","LU0859254822.USD","LU0957808578.USD","LU1496350171.SGD","IE00BMPRXR70.SGD","LU1814569148.SGD","NVC","LU0203345920.USD","LU0203201768.USD","BK4533","SPCQ","HK0000914686.HKD","IE00BJTD4V19.USD","HK0000320223.HKD","IE00BK4W5M84.HKD","LU1732799900.SGD","LU2097344431.USD","LU2456880835.USD","LU0889565833.HKD","LU0792757196.USD","IE00BN29S564.USD","LU0053666078.USD","LU1551013342.USD","LU1244550494.USD","LU2452424414.USD","LU2089283258.USD","IE00BK4W5L77.USD","LU0267386448.USD","HWAY","LU2111349929.HKD","SNK","LU1852331112.SGD","LU0342679015.USD","LU1035775433.USD","IE0004086264.USD","LU2322448957.HKD","LU0265550946.USD","LU2168564149.EUR","LU1548497426.USD","LU2237443549.SGD","LU2361044865.SGD","SOXX","BK4141","LU0823414551.USD","LU1732800096.USD","LU2592432038.USD","LU2552382058.USD","LU0289739343.SGD","IE00BHPRN162.USD","LU2065171311.SGD","LU2491049909.HKD","LU0251132253.USD","BK4529","LU1037948541.HKD","LU2471134879.HKD","LU1983260115.SGD","SG9999015341.SGD","SNVDAmain","IE00B775SV38.USD","LU0097036916.USD","NVDX","SHOC","LU2237438978.USD","LU0109391861.USD","LU1119994496.HKD","LU0353189763.USD","LU0128525929.USD","LU0323591593.USD","LU2191332357.HKD","BK4503","LU0345769631.USD","BK4592","SG9999018865.SGD","LU1880398471.USD","LU2023251221.USD","LOFF","LU0820562030.AUD","MU","PTF","LU0061474705.USD","IE0034235188.USD","LU2168563687.JPY","LU1791710582.SGD","SGXZ81514606.USD","CHPS","LU1712237335.SGD","LU0395794307.EUR","BK4598","LU1917777945.USD","JGRO","LU2272731600.USD","LU0238689110.USD","IE00BKVL7J92.USD","LU0138981039.USD","SOXY","LU0738911758.USD","SG9999015358.SGD","IE00BMPRXQ63.HKD","IE00BQXX3D17.EUR","LU1645745479.HKD","SG9999014567.USD","LU2347655156.SGD","LEGR","NVYY","LU2279689827.SGD","LU0072462426.USD","CLSE","LU1839511570.USD","LU1674673428.USD","LU0494093205.USD","IE000W1ABFV2.USD","LU2999663052.SGD","RSHO","SG9999002232.USD","LU1951198990.SGD","LU1571399168.USD","IE00B1BXHZ80.USD","LU1699723380.USD","LU1323610961.USD","LU2211815571.USD","SG9999018857.SGD","LU1084165304.USD","LU0070217475.USD","LFGY","DSPC","DISK","BK4549","BK4567","IE00B1XK9C88.USD","SG9999014898.SGD","BK4587","GNOM","LU1066051498.USD","LU0175139822.USD","LU1815336760.USD","SG9999015952.SGD","LU0683600562.USD","LU2473716301.USD","LU0957791311.USD","LU0820561909.HKD","LU2237957811.SGD","LU0158827948.USD","LU0048573561.USD","LU0210533765.USD","LU2102340556.USD","LU2286300806.USD","NVDS.UK","LU0726765562.USD","LU1721428933.USD","HK0000306701.USD","LU0708995401.HKD","LU0661504455.SGD","LU1069347547.HKD","TRUI","LU1400636574.HKD","IE00B19Z3581.USD","BK4149","LU1244550577.SGD","LU2471134796.USD","SG9999004303.SGD","LU2290526834.HKD","IE00BJTD4N35.SGD","LU2403377893.USD","NVDL","LU0719512351.SGD","LU1069344957.HKD","EGGY","NVDO","RULE","BK4588","LU0203202063.USD","BAI","LU2250418816.HKD","LU0353189680.USD","LU1232071149.USD","TTXU","DRMY","IE0002270589.USD","IE0003U64NQ7.SGD","TRFK","LU0417517546.SGD","LU2360106780.USD","LU2413666699.HKD","ESLG","LOFD","LU1267930573.SGD","TTEQ","LU1633808545.USD","IE00BDCRKT87.USD","BK4597","WUGI","IE00BQXX3F31.USD","LU0234572021.USD","AIFD","LU2148611432.USD","LU0985320562.USD","LU2023250504.SGD","LU1861559042.SGD","LU2931357623.SGD","CGGO","LU2272731782.SGD","LU0672654240.SGD","LU1629891620.HKD","HK0000819398.USD","LU2237443465.HKD","BK4581","NVDU","SG9999014559.SGD","LU0354030438.USD","BK4553","LU0444973449.USD","LU0640476718.USD","LU0965509101.SGD","LU2271345857.HKD","LU0174119429.USD","LU1821325948.USD","WLDR","LU0082616367.USD","LU1144417596.USD","HK0000320264.USD","IE000Q6AESB8.SGD","LU1914381329.SGD","LU1923622614.USD","NVDA","LU1880398554.USD","LU0942090050.USD","LU0187121727.USD","LU1153585028.USD","LU0476273544.USD","LU2237443895.HKD","SOXQ","EMSF","CMAG","LU0511384066.AUD","LU1934455863.HKD","LU0868494708.USD","LU2237957902.USD","IE00B5949003.HKD","TYLG","LU2249611893.SGD","LU0094547139.USD","LU2420271590.USD","LU1868836757.USD","LU2361045086.USD","MRNY","LU1066051225.USD","LU2168564495.EUR","LU1803068979.SGD","LU2108987350.USD","LU0133085943.USD","LU2458330243.SGD","LU2462157665.USD","BK4608","SMH","BK4089","LU2357305700.SGD","LU0210528500.USD","LU2089284900.SGD","LU0965509283.SGD","SGXZ99366536.SGD","BK4516","SMU00main","BK4614","NVDD","LU2322448791.USD","LU1116320737.USD","LU0310799852.SGD","LU0472753341.HKD","MUYY","LU0096364046.USD","LU0912757837.SGD","IE00B19Z8X17.USD","ESUM","LU0528227936.USD","IE00BFSS8Q28.SGD","SSPC","LU2065170008.USD","LU2750360641.GBP","SG9999015978.USD","IE00B775H168.HKD","HK0000306685.HKD","LU2089985449.USD","LU1642822529.SGD","LU0276348264.USD","LU1804176565.USD","LU0096362180.USD","LU1935042991.SGD","LU2236285917.USD","LU0354030511.USD","IE00BZ199S13.USD","LU1435385759.SGD","LU2054465674.USD","LU2125909916.SGD","LU2430703251.USD","LU2458330169.SGD","MIC","SG9999014542.SGD","LU0345768740.USD","SPCM","IE0034235295.USD","LU1988902786.USD","AIQ","SPCU","LU1366192091.USD","LU0256863811.USD","LU0056508442.USD","IE000YTNTUN2.SGD","LU1242518931.SGD","LU2247934214.USD","LU0157215616.USD","LU2125909593.SGD","LU2242650005.HKD","LU0048584097.USD","LU1202635105.USD","LU3102509885.SGD","CHAT","SG9999001424.SGD","IE00BJJMRX11.SGD","LU1244550221.USD","BK4520","LU1066051811.HKD","MUZ","LU0466842654.USD","LU0345768153.USD","LU2237443382.USD","LU0345769128.USD","ROM","THMR","LU2097344357.USD","LU0943347566.SGD","VT","IE0001KFT4U8.USD","LU0788109477.HKD","IE00B5TLWC47.USD","LU2028103732.USD","IE00B19Z9505.USD","LU0444971666.USD","LU1868836591.USD","LU1992135472.HKD","LU2471134523.USD","BK4575","LU1935042488.USD","LU2394011477.USD","TEK","SNVD.UK","LU1803068623.USD","LU1267930730.SGD","LU2756315664.SGD","PSI","LU0949170772.SGD","LU0898699433.AUD","LU2294711713.HKD","LU1400636657.SGD","LU0390134368.USD","LU1989764748.USD","SPAX","LU1934455277.USD","LU2462591277.SGD","LU0795875169.SGD","LU2023250330.USD","LU1868836914.USD","LU1992135399.USD","ILDR","LU1923622291.USD","HBMX","LU0964807845.USD","LU1935043536.SGD","LU1989772840.SGD","UXI","LU1951200564.SGD","LU1868837136.USD","LU0348723411.USD","LU0823434583.USD","LU0820561818.USD","IDNA","LU1066053197.SGD","BK4534","SGXZ23171101.USD","SPCF","LU0553294199.USD","IE00BD6J9T35.USD","LU2065169927.USD","LU0029864427.USD","IE0004445015.USD","LU1267930490.SGD","IE00BKDWB100.SGD","IXN","LU0557290698.USD","VGT","LU0320765059.SGD","IE00B19Z3B42.SGD","METV","LU0158827781.USD","LU1861220033.SGD","LU2756315318.SGD","AIS","NVDB","LU2381873111.SGD","ABFL","SG9999015986.USD","LU2746668461.USD","WISE","LU0689472784.USD","IE00BJLML261.HKD","NVD","IE0005OL40V9.USD","LU2361044949.HKD","BK4543","IE00BSNM7G36.USD","BK4579","LU0323239441.USD","SG9999014906.USD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673483150","title":"Moderna Inc. Stock Rises 4.8%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2673483150","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673483150?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:33","pubTimestamp":1791405180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. advanced 4.8% to $196.48 on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 0.2% to 27,538.69 and Dow Jones Industrial Average falling 0.7% to 51,179.87.Moderna Inc. closed 7.4% short of its 52-week high of $212.22, which the company achieved on October 6th.The stock outperformed some of its peers, as Johnson & Johnson rose 1.4% to $258.45, Pfizer Inc. rose 1.8% to $28.00, and Gilead Sciences Inc. rose 1.82% to $146.85.Trading volume totaled 14.6 million, compared to the 50-day average of 20.7 million.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","LU0823416689.USD","SG9999015978.USD","LU0109394709.USD","IE00B7SZLL34.SGD","LU1839511570.USD","BMED","IE00BKVL7J92.USD","IE00B3T34201.USD","BIB","BK4578","IDNA","IE00BZ1G4Q59.USD","MRNX","IE00B19Z3581.USD","MRNA","BK4585","BK4588","LU0861579265.USD","LU1778281490.HKD","IBB","LU2112291526.USD","MRNY","GNOM","LU0289739699.SGD","LU1674673428.USD","LU1061106388.HKD","IE00BSNM7G36.USD","LU0965508806.USD","TMED","BK4534","IE0002270589.USD","BK4566","LU0965509010.AUD","IBBQ","GILD","LU0058720904.USD","BK4550","SG9999015952.SGD","BK4551","BK4583","BK4501","LU2324357040.USD","TBXU","SG9999015986.USD","BK4548","WDNA","LU2089984988.USD","BBH","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673101011","title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 910,033 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673101011","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673101011?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:05","pubTimestamp":1791403549,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO Emily M. Leproust disposes of USD 910,033 in common sharesTwist Bioscience CEO Emily M. Leproust sold 4,548 shares of common stock on Oct. 5, 2026.Sales were disclosed at weighted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDLthKxF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 910,033 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","ARKG","TWST","BK4139","GNOM","IDNA","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673106080","title":"Vertex to Report Q3 2026 Financial Results, Host Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2673106080","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673106080?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:00","pubTimestamp":1791403217,"startTime":"0","endTime":"0","summary":"Vertex to report Q3 2026 financial results, host conference call and webcastVertex will report third-quarter 2026 financial results on Nov. 2, 2026.Conference call and webcast set for Nov. 2, 2026 at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL13mQMk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","PBE","LU2462157665.USD","IE0009355771.USD","LU0234570918.USD","BK4532","LU0889565916.HKD","LU2468319806.SGD","IDNA","BK4139","LU0058720904.USD","VRTX","BBH","GNMX","BK4567","LU0079474960.USD","LU1035775433.USD","LU0432979614.USD","LU0256863811.USD","SG9999001176.USD","SGXZ57979304.SGD","LU1093756325.SGD","LU1674673691.USD","LU2324357040.USD","LU2456880835.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU2237438978.USD","TBXU","IE00B894F039.SGD","IE00B19Z9P08.USD","IE0002141913.USD","IE00B19Z3B42.SGD","SG9999013999.USD","IE00B19Z9Z06.USD","LU0823416689.USD","BK4588","IE00BJT1NW94.SGD","LU1430594728.SGD","LU0109394709.USD","BK4585","LU1674673428.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2362541513.USD","LU2089984988.USD","SG9999001176.SGD","BIB","LU0320765992.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011275","title":"Moderna, Merck Climb on Collaboration with Tempus","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011275","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011275?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:33","pubTimestamp":1791390807,"startTime":"0","endTime":"0","summary":"BUZZ-Moderna, Merck climb on collaboration with Tempus** Pharmaceutical companies ModernaMRNA.Oand MerckMRK.Oclimb 3.25% to $193.56 and 1.46% to $144.01, respectively** AI healthcare technology compan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T116:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU2468319806.SGD","LU1929549753.HKD","BK4559","IXJ","LU1585245621.USD","LU1069347547.HKD","LU0320765646.SGD","LU1057294990.SGD","LU0289961442.SGD","SG9999014542.SGD","SG9999013999.USD","LU1699723380.USD","BK4550","LU0070302665.USD","BK4121","LU2112291526.USD","MRNA","LU0980610538.SGD","LU1037948897.HKD","LU0106261372.USD","LU2125909593.SGD","LU1917777945.USD","LU2106854487.HKD","LU1093756168.USD","LU1934455863.HKD","LU0266013472.USD","LU0058720904.USD","TEM","BMED","IE0009355771.USD","LU1066051498.USD","LU2433249047.HKD","HRTS","LU2125154778.USD","LU1934455277.USD","IE00BBT3K403.USD","LU0098860793.USD","MRNY","IE000M9KFDE8.USD","LU1923622614.USD","LU0289739699.SGD","LU1934455194.USD","SG9999001176.USD","XLV","SG9999001176.SGD","PPH","LU1035773651.USD","LU0289739343.SGD","LU0162691827.USD","IDNA","LU0238689110.USD","LU2125154935.USD","HEAL","GNOM","SG9999002232.USD","LU1201861249.SGD","BK4532","MRK","LU0942090050.USD","LU1116320901.HKD","BK4007","IE00BN8TJ469.HKD","IE00B4R5TH58.HKD","BK4568","IHE","LU0965509101.SGD","LU2023250504.SGD","LU1861558580.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU0648001328.SGD","BK4613","LU0859254822.USD","LU2357627491.SGD","LGHT","RXL","LU0965509010.AUD","LU0069063385.USD","LU1974910355.USD","BK4139","SG9999002224.SGD","LU0057025933.USD","BK4611","BK4533","GDOC","LU1430594728.SGD","TEMT","LU0985320562.USD","IE00BLSP4452.SGD","BK4501","ARKG","IE00BLSP4239.USD","LU0861579265.USD","IE00BFTCPJ56.SGD","LU0124676726.USD","LU0265550359.USD","LU1291159041.SGD","MRNX","LU1023059063.AUD","LU1941712264.USD","SG9999014559.SGD","LU1032466523.USD","LU1989771016.USD","LU2361044949.HKD","LU0965509283.SGD","LU2361045086.USD","LU2361044865.SGD","LU0689626769.HKD","LU1983299246.USD","LU0203347892.USD","LU0868494708.USD","BK4551","LU0211331839.USD","IYH","LU0122379950.USD","LU2324357040.USD","LU1116320737.USD","LU1066051811.HKD","LU0234572021.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","LU0203345920.USD","LU1066053197.SGD","LU1162221912.USD","LU1061106388.HKD","BK4588","SG9999015358.SGD","SG9999001440.SGD","LU0823416689.USD","TRUH","LU2360032135.SGD","LU0432979614.USD","LU2456880835.USD","SG9999014575.USD","LU0208291251.USD","LU0265550946.USD","LU1571399168.USD","BK4585","WDNA","JDOC","SG9999014567.USD","BK4534","LU1989772923.USD","LU1941712348.USD","FTXH","VHT","IE00B1BXHZ80.USD","LU0477156953.USD","BK4548","LU1989772840.SGD","LU2125909247.SGD","LU2461242641.AUD","LU0006306889.USD","LU0130102774.USD","IE0002141913.USD","LU2236285917.USD","LU0320765489.SGD","LU0868494617.USD","LU0472753341.HKD","IE00B2B36J28.USD","LU1861559042.SGD","LU1093756325.SGD","LU1037948541.HKD","LU0511384066.AUD","LU2089984988.USD","TEMC","IE00BSNM7G36.USD","LU2491050071.SGD","PAWZ","LU2491049909.HKD","LU2417539215.USD","LU0072461881.USD","BK4516","LU2491050154.USD","LU0965508806.USD","LU2023250843.SGD","LU1066051225.USD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011453","title":"Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011453","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011453?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:15","pubTimestamp":1791389721,"startTime":"0","endTime":"0","summary":"• Amgen rose due to positive analyst commentary and strong third-quarter financial forecasts.\n• Robust commercial execution and advancing clinical pipeline drove higher investor confidence.\n• Strong balance sheet and favorable technical indicators continue attracting institutional capital.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262204356-market-movers-amgn-20261007","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","WDNA","HRTS","CURE","OZEM","IBBQ","CANC","VHT","TRUH","LU0708995401.HKD","LU2242646821.SGD","JDOC","LLYX","LU1323610961.USD","PBE","ILDR","PPH","BMED","AGNG","IBB","IHE","THNR","LU1221951046.USD","MHIP","FHLC","GDOC","MRNX","IDNA","LLYZ","JNJ","LLII","IYH","MRNA","RXL","FTXH","MRNY","IXJ","XLV","GNOM","ELIS","PJP","LLY","TMED","LGHT","MEDX","TBXU","BIB","ELIL","BBH","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673526011","title":"S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2673526011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673526011?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:00","pubTimestamp":1791388809,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500.SPXTop PerformersPercent ChangeEli Lilly and CompanyLLY.N+3.9%ResMed Inc.RMD.N+3.6%Hewlett Packard Enterprise CompanyHPE.N+3.3%Rollins IncROL.N+3.2%Moderna, Inc.MRNA.OQ+3.2%Bottom PerformersPercent ChangeEMCOR Group, Inc.EME.N-6.3%Comfort Systems USA, Inc.FIX.N-6.3%Caterpillar IncCAT.N-5.9%Teradyne, Inc.TER.OQ-5.8%Allegion PLCALLE.N-5.7%As of 12:00 p.m., the S&P 500.SPXlost 27.60 points, or 0.35%, to 7,791.33 and had posted 8 new 52-week highs and 10 new lows.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL8N45T1JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4551","XLG","LU0210536198.USD","AGNG","SPMO","IVE","LU2237443895.HKD","BK4504","LU2237438978.USD","LU0820561818.USD","LU0094547139.USD","LU0097036916.USD","ITOT","DBSC","LU0708995401.HKD","LU2168564495.EUR","IHE","FIX","LU0786609619.USD","LU2357305700.SGD","LU2112291526.USD","IE00BK4W5L77.USD","LU2417539215.USD","PPH","BK4149","LU0689472784.USD","LU0225283273.USD","LU2063271972.USD","LU1093756325.SGD","LU0079474960.USD","LU2462591350.SGD","IE00BK4W5M84.HKD","LU0256863902.USD","SGXZ81514606.USD","LU2271345857.HKD","LU2023250504.SGD","LU0820562030.AUD","LU2552382132.HKD","LU0742534661.SGD","LU2237443978.SGD","LU0787776722.HKD","LU1712237335.SGD","LU0942090050.USD","IE00BJJMRY28.SGD","IVW","LU2023250330.USD","LU0174119429.USD","LU0957808578.USD","IE0004445239.USD","LU0225284248.USD","LLII","VHT","SPXU","LU2552382215.SGD","LU2756315664.SGD","SMAX","SPY","BK4534","LU0432979614.USD","SG9999014914.USD","LU0006061336.USD","CURE","LU0158827781.USD","TSPY","SCHB","LU2543165471.USD","IE00BN0W2V16.EUR","SPXS","UPRO","LU1923622291.USD","JDOC","HWAY","LU2896262040.SGD","MEDX","LU0203202063.USD","LU2237443465.HKD","IE00BJJMRZ35.SGD","LU2023251221.USD","ILDR","LU0385154629.USD","SG9999013999.USD","FTXH","LU1057294990.SGD","BK4501","LU0868494617.USD","LU2324357040.USD","LU2108987350.USD","DMAX","LU0882574139.USD","LU2168563687.JPY","LLY","LU0203345920.USD","EPAI","LU2211815571.USD","NOBL","SPYM","IE00BN29S564.USD","IE00B7KXQ091.USD","IE00BFSS7M15.SGD","SG9999015978.USD","LU0820561909.HKD","LU2089984988.USD","VEU","LU0274383776.USD","IE0001KFT4U8.USD","LU0640476718.USD","TRUI","BK4007","RSP","IE00B4R5TH58.HKD","SPXL","IE00BMPRXQ63.HKD","LU0353189763.USD","IE00BKDWB100.SGD","IE00BD6J9T35.USD","IYH","SG9999001176.USD","SPYU","LU0823434583.USD","IE0034235188.USD","LU0256863811.USD","SPYD","LU0320765059.SGD","LU2602419157.SGD","GASZ","SPLV","OZEM","IE00B1XK9C88.USD","MRNX","LU0321505868.SGD","LU0964807845.USD","LU1069344957.HKD","IJR","VV","LU0109394709.USD","RXL","IE00BN0W2T93.GBP","SH","THNR","HPE","LU2168564065.EUR","IE00B775H168.HKD","LU2168564222.USD","LU0170899867.USD","LU0456855351.SGD","LU1548497426.USD","HIBS","IE00BKPKM429.USD","IJH","IE00BJJMRX11.SGD","LU1868837136.USD","ETFT","LU0985481810.HKD","IE0002141913.USD","LU1145028129.USD","CATG","SPHQ","LU2213496289.HKD","BK4548","LU0354030438.USD","LU0203201768.USD","LU0348723411.USD","SG9999014906.USD","LU1642822529.SGD","LU2028103732.USD","SG9999014898.SGD","LU0417517546.SGD","LU1868836914.USD","LU1720051108.HKD","TERC","UXI","LU1814569148.SGD","LU0683600562.USD","LLYZ","LU0061475181.USD","LU0251131958.USD","TMED","LU2746668461.USD","LU2746668974.SGD","LU0006306889.USD","LU0054578231.USD","HRTS","XDTE","LU2471134523.USD","LU2089284900.SGD","LU1127390331.HKD","BK4532","SG9999015945.SGD","ACWI","LU1868837300.USD","LU2237443622.USD","HPEL","GPIX","LU0943347566.SGD","LU0471298777.SGD","LU2471134796.USD","IDNA","LU1974910355.USD","LU1868836757.USD","LU0203347892.USD","LU1023059063.AUD","BK4147","LU2361044865.SGD","LU2468319806.SGD","FHLC","MEDI","BK4516","LU0106261372.USD","LU1232071149.USD","SCHX","LU1988902786.USD","ROL","LU1061106388.HKD","IE00B2B36J28.USD","LU1804176565.USD","GB00BDT5M118.USD","LU1323610961.USD",".SPX","LU2237443382.USD","BK4567","LU0316494557.USD","LU0198837287.USD","RSPN","BK4170","BK4588","LU0109391861.USD","MRNY","LU0320765992.SGD","LU2756315318.SGD","SPYG","BK4129","LU2456880835.USD","LU0048573561.USD","RSPA","TRUH","LU0133085943.USD","MADE","SGXZ31699556.SGD","SPYV","IE00BN0W2W23.USD","LU2461242641.AUD","LU0868494708.USD","LU1035775433.USD","ALLW","LU0963586101.USD","SGXZ57979304.SGD","CAT","IE00B4JS1V06.HKD","SPYH","LU2360106947.USD","BK4568","LU1267930730.SGD","LU1979441026.SGD","SG9999015952.SGD","LU2106854487.HKD","LU0058720904.USD","YSPY","LGHT","LU1868836591.USD","IE00BFSS8Q28.SGD","LU1861559042.SGD","LU0096364046.USD","LLYX","LU0672654240.SGD","SPGP","IE00BSNM7G36.USD","PJP","WDNA","ELIL","CANC","LU1064131342.USD","LU2361045086.USD","SPDN","MHIP","LU2089283258.USD","IE00BWXC8680.SGD","SPUU","LU2177674079.SGD","LU1551013425.SGD","HIBL","LU0345770993.USD","LU0238689110.USD","SFY","HVAC","LU2750360641.GBP","MMAX","SG9999018865.SGD","LU1691799644.USD","ELIS","BK4120","SPHD","LU0354030511.USD","LU2168564149.EUR","GSLC","LU0882574055.USD","VOOG","TERG","LU0306806265.USD","LU2125909759.SGD","SSO","LU1551013342.USD","VTV","EXI","AIRR","SGXZ99366536.SGD","IE00BJT1NW94.SGD","SPYQ","SGXZ51526630.SGD","LU2462157665.USD","LU1983299246.USD","LU2471134879.HKD","RSHO","LU0466842654.USD","LU2087625088.SGD","BK4086","LU1720051017.SGD","GDOC","MRNA","SG9999018857.SGD","LU0122379950.USD","SG9999014880.SGD","IXJ","LU0823416689.USD","LU1815336760.USD","VTI","BK4599","LU2237443549.SGD","RSPU","IE0009355771.USD","BK4543","IE00BMPRXN33.USD","LU0345770308.USD","LU1291159041.SGD","XLV","LU2471134952.CNY","XYLD","LU0444971666.USD","LU2552382058.USD","LU0158827948.USD","BK4581","LU2264538146.SGD","LU2491050071.SGD","LU0471298694.HKD","LU0289739699.SGD","IE00BMPRXR70.SGD","BK4082","IE0005OL40V9.USD","IE00B1BXHZ80.USD","BK4597","LU1917777945.USD","LU0823434740.USD","LU0053671581.USD","BMAY","LU2491050154.USD","BK4533","LU2265009873.SGD","LU2111349929.HKD","LU0266013472.USD","VBK","LU1629891620.HKD","EME","SDS","SG9999015986.USD","LU0251142724.SGD","LU1366192091.USD","LU2361044949.HKD","LU0114720955.EUR","SG9999017495.SGD","BK4139","LU0225771236.USD","TER","SPUS","LU1093756168.USD","ALLE","LU1861558580.USD","IVV","IE00BJLML261.HKD","LU2125909916.SGD","BK4520","LU2008162690.USD","VOO","BK4585","LU1623119135.USD","LU0321505439.SGD","LU0306807586.USD","LU0353189680.USD","LU1280957306.USD","RMD","LU0234572021.USD","LU2750360997.AUD","IE00B5TLWC47.USD","LU0889565916.HKD","SG9999001176.SGD","LU2491049909.HKD","LU2236285917.USD","IE0004445015.USD","MOAT","BK4515","LU0323591593.USD","LU1989771016.USD","GNOM","JEPI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","MEDX","LU0070302665.USD","XLVX","NVIB","LU0208291251.USD","IE00BJT1NW94.SGD","BMED","LFSC","IYH","LABU","FRTY","BK4585","BK4588","BBP","BK4007","MEDI","IEIH","TECB","GNMX","PINK","BK4578","MRNY","LU0320765489.SGD","IE0002141913.USD","IBB","SYNB","TBXU","GDOC","IDNA","BK4532","MRNX","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","RSPH","NVS","IE00BJJMRZ35.SGD","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1064131342.USD","LU1720051108.HKD","LU0210528500.USD","LU1668664300.SGD","LU0528227936.USD","LU0267386448.USD","MEDI","PINK","LU2089284900.SGD","PSCH","KBWB","LU2357305700.SGD","LU2487616109.SGD","SD","TBXU","TECB","BK4581","LFSC","MRNX","LABU","BK4585","LU1720051017.SGD","LU0390134368.USD","NVIB","FRTY","IBB","BK4504","LU0912757837.SGD","BBP","LU1791710582.SGD","IEIH","LU2028103732.USD","BMED","MRNY","XLVX","LU1244550221.USD","LU0795875169.SGD","SYNB","RSPH","LU2023251221.USD","GDOC","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU0106831901.USD","IE00B3S45H60.SGD","LU1989772840.SGD","IYH","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673019052","title":"Twist Bioscience Price Target Raised to $215.00/Share from $112.00 by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673019052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673019052?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:42","pubTimestamp":1791387720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TWST/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TWST","ARKG","IDNA","GNOM","WDNA","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673312019","title":"Moderna Price Target Raised to $95.00/Share from $89.00 by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2673312019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673312019?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:02","pubTimestamp":1791385320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRNA/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","BK4534","BK4501","BK4551","BK4139","BK4568","BK4588","GNOM","BK4532","BK4548","MRNA","MRNX","BK4585","MRNY","LGHT","BK4533","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013770","title":"AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013770","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013770?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:14","pubTimestamp":1791378840,"startTime":"0","endTime":"0","summary":"CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development Access the article here OCALA, Fla., Oct.  07, 2026 (GLOBE NEWSWIR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376540/29489/en/aim-immunotech-s-strategy-to-address-immune-resistance-in-pancreatic-cancer-featured-in-biotuesdays.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","NVIB","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":3,"totalSize":202,"code":"91000000","status":"200"}]}}